|
CNBC'S MOST SHARED
- WPP's Sir Martin Sorrell on the Ad Recession
- Unemployed? Bored? Make Money Playing Beer Pong
- Social Networking's 'Naked' Truth
- Merrill's McCann Seen as UBS Wealth Frontrunner
- The View From Newark
- Warren Buffett's Top Three Investment Rules for the Average American
- Preparing for Retirement
- Earnings 101: Beyond The Big Names
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- GM IPO in Second Quarter 2010 at the Earliest: CFO
- Merrill's McCann Seen as UBS Wealth Frontrunner
- It's Not the Wealthy Who Are Leaving California: Study
- Atlantic City Takes Hit as Pennsylvania Casino Opens
Text Size 
 |
] announced it's stopping production of its new anti-cholesterol drug torcetrapib. Unfortunately--clinical test results showed there were more deaths than expected from taking the experimental drug.Catherine Arnold is a pharmaceutical analyst from Credit Suisse. While on "Squawk Box" Arnold said this is obviously a big deal for the world's largest drug company--and said her firm has lowered their target price for the stock from $28 a share to $24. Fair value says Arnold would be $23 to $24 a share. Arnold says she is neutral on the stock (analyst disclosure-Credit Suisse is an investment bank client of Pfizer). The stock is expected to see dramatic losses today.
Arnold says this certainly raises questions about the effect of pharmaceutical drugs improving health--and it's double troubling for Pfizer which could lose 25% of its revenue source with the loss of torcetrapib.
Torcetrapib is supposed to increase the good cholesterol or HDL. It was the most important drug in Pfizer's new line of products--and a follow up to the company's lipitor drug. The company thought it would be a "blockbuster" and had been praising the new drug.
Pfizer CEO Jeff Kindler will be on "Power Lunch" today to talk about what happened.
Data is a real-time snapshot *Data is delayed at least 15 minutes